Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
Compugen will present a trial-in-progress poster for its Phase 1 MAIA-ovarian study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The poster, presented by Dr. Oladapo Yeku of Massachusetts General Hospital, evaluates COM701 as a maintenance treatment in relapsed platinum-sensitive ovarian cancer.
Key figures
- Drug Name
- COM701
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.